Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History VNDA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics VNDA

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Vanda Pharmaceuticals Inc

VNDA
Current price
4.74 USD -0.25 USD (-5.01%)
Last closed 4.99 USD
ISIN US9216591084
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 294 083 136 USD
Yield for 12 month -21.26 %
1Y
3Y
5Y
10Y
15Y
VNDA
21.11.2021 - 28.11.2021

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) a LAI formulation to treat schizophrenia; Bysanti for the acute treatment of bipolar I disorder, schizophrenia, and major depressive disorder; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, and atopic dermatitis. The company's pipeline products also include Imsidolimab, an IL-36R antagonist, for the treatment of generalized pustular psoriasis; VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; VPO-227 for the treatment of secretory diarrhea disorders comprising cholera; Antisense oligonucleotide molecules, including VCA-894A for the treatment of Charcot-Marie-Tooth Disease and Type 2S (CMT2S); and VGT-1849A for the treatment of polycythemia vera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia. Address: 2200 Pennsylvania Avenue NW, Washington, DC, United States, 20037

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

12.67 USD

P/E Ratio

Dividend Yield

Financials VNDA

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures VNDA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+198 772 000 USD

Last Year

+192 640 000 USD

Current Quarter

+50 041 000 USD

Last Quarter

+53 185 000 USD

Current Year

+187 458 000 USD

Last Year

+192 640 000 USD

Current Quarter

+46 520 000 USD

Last Quarter

+48 843 000 USD
EBITDA -64 562 000 USD
Operating Margin TTM -81.99 %
Price to Earnings
Return On Assets TTM -7.05 %
PEG Ratio -2.42
Return On Equity TTM -8.39 %
Wall Street Target Price 12.67 USD
Revenue TTM 201 351 008 USD
Book Value 8.68 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 5.40 %
Dividend Yield
Gross Profit TTM 189 956 000 USD
Earnings per share -0.76 USD
Diluted Eps TTM -0.76 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY -95.90 %
Profit Margin -21.98 %

Stock Valuation VNDA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 30.30
Enterprise Value Revenue 0.59
Price Sales TTM 1.46
Enterprise Value EBITDA 12.91
Price Book MRQ 0.58

Technical Indicators VNDA

For 52 Weeks

3.81 USD 6.37 USD
50 Day MA 4.48 USD
Shares Short Prior Month 4 726 102
200 Day MA 4.63 USD
Short Ratio 10.60
Shares Short 4 686 596
Short Percent 8.32 %